Merck 1Q Revenues: $15.8 billion (+9%) 1Q Earnings: $4.8 billion (+69%) Comments: Keytruda sales were $6.9 billion in the quarter, up 20% driven by increased global uptake in earlier-stage indications, including triple-negative breast cancer and renal cell carcinoma, as well as non-small cell lung cancer (NSCLC) in the U.S. Gardasil sales were up 14% to $2.2 billion. Januvia sales were down 24% to $670 million, primarily due to lower pricing and demand in the U.S., as well as ongoing generic ...